We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Vaccinex Inc (VCNX) USD0.0001

Sell:$1.12 Buy:$1.12 Change: $0.19 (14.50%)
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Sell:$1.12
Buy:$1.12
Change: $0.19 (14.50%)
Deal now Deal for just £11.95 per trade in a Fund and Share Account
Deal now
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Sell:$1.12
Buy:$1.12
Change: $0.19 (14.50%)
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Vaccinex, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical development for the treatment of Alzheimer’s disease, head and neck, pancreatic and breast cancer. Its lead platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop pepinemab for the treatment of various diseases and conditions, including cancer. ActivMAb antibody discovery platform is a human antibody discovery platform based on a method for expressing multipass membrane proteins, as well as large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of mammalian pox viruses.

Contact details

Address:
1895 Mount Hope Ave
ROCHESTER
14620-4540
United States
Telephone:
+1 (585) 2712700
Website:
https://www.vaccinex.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
VCNX
ISIN:
US9186403013
Market cap:
$3.00 million
Shares in issue:
2.68 million
Sector:
Biotechnology
Exchange:
Off Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Albert Friedberg
    Chairman of the Board
  • Maurice Zauderer
    President, Chief Executive Officer, Director
  • Jill Sanchez
    Interim Chief Financial Officer
  • Elizabeth Evans
    Chief Operating Officer, Senior Vice President - Discovery and Translational Medicine
  • Ernest Smith
    Senior Vice President - Research, Chief Scientific Officer
  • John Leonard
    Senior Vice President - Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.